Present study |
2024 |
13 |
Illumina MiSeq, NGS custom panel |
10× KRAS, 9× TP53, 4× CDKN2A, 1× SMAD4, CIC, GNAS, APC, ATM, NF1, FBXW7, ATR, FGFR3
|
Yang et al. [27] |
2020 |
1 |
Whole exome sequencing |
1× KRAS, 1× BRCA2
|
Luchini et al. [6] |
2017 |
8 |
Illumina HiSeq, whole exome sequencing
|
8× KRAS, 7× TP53, 3× TTN, 2× CDKN2A, SERPINA3, MAGEB4, GLI3, MEGF8, 1× SMAD4
|
Lukáš et al. [23] |
2006 |
2 |
PCR
|
2× KRAS wild type, 2× TP53 wild type |
Sedivy et al. [28] |
2005 |
1 |
PCR
|
1× KRAS
|
Sakai et al. [24] |
2000 |
3 |
PCR
|
3× KRAS
|
Imai et al. [21] |
1999 |
3 |
PCR |
3× KRAS
|
Deckard-Janatpour et al. [22] |
1998 |
6 |
PCR |
5× KRAS
|
Westra et al. [25] |
1998 |
5 |
PCR |
4× KRAS
|
Hoorens et al. [26] |
1998 |
1 |
PCR |
1× KRAS
|